NICE issues final approval for Gazyvaro in chronic lymphocytic leukaemia
From today, clinicians in England and Wales will be able to prescribe Roche's Gazyvaro for eligible patients with chronic lymphocytic leukaemia (CLL) on the NHS.
List view / Grid view
From today, clinicians in England and Wales will be able to prescribe Roche's Gazyvaro for eligible patients with chronic lymphocytic leukaemia (CLL) on the NHS.
1 June 2015 | By Victoria White
Results from a Phase III study show that Gazyvaro provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL)...
1 June 2015 | By Victoria White
Roche has announced new results from the Phase II NeoSphere study that assessed a Perjeta regimen in people with HER2-positive early breast cancer...
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...
14 May 2015 | By Victoria White
Results from two pivotal studies have shown that alectinib shrank tumours in people with advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)...
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
8 April 2015 | By Victoria White
The EU has approved Avastin in combination with chemotherapy for the treatment of persistent, recurrent or metastatic carcinoma of the cervix...
11 March 2015 | By Roche
New option for patients as NICE accepts Gazyvaro® (obinutuzumab) for treatment of most common adult leukaemia...
4 March 2015 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
2 March 2015 | By Roche
Combination of Avastin and chemotherapy would be the first new treatment in advanced cervical cancer to extend life in nearly a decade...
2 March 2015 | By Roche
Roche announced that it has extended the expiration of its tender offer to purchase up to 15,604,288 of the outstanding common shares of Foundation Medicine, Inc...
19 February 2015 | By Roche
Roche announced the U.S. Food and Drug Administration has accepted and granted priority review for the company’s New Drug Application for cobimetinib in combination with Zelboraf® (vemurafenib) for the treatment of people with BRAF V600 mutation-positive advanced melanoma...
9 February 2015 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Lucentis® (ranibizumab injection) for the treatment of diabetic retinopathy, in people with diabetic macular edema...
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...